Linguistic features in re.Karthigesu's Novels: an overview from a stylistic perspective by Ramasamy, K.

Get full text

Dividends, short selling restriction, tax-induced investor clienteles and market equilibrium / by 284580 Litzenberger, R H, Ramasamy, K.

Optimal power allocation for the proposed asymmetric turbo code for 3G systems by Ramasamy, K., Balamuralithara, B., Siddiqi, Muhammad Umar

Get full text

Performance evaluation of proposed asymmetric turbo code in WCDMA HSDPA system by Ramasamy, K., Balamuralithara, B., Siddiqi, Mohammad Umar

Get full text

Modelling of carbon dioxide absorption in aqueous solutions of AMP and MDEA and their blends using Aspenplus by Aroua, M.K., Haji-Sulaiman, M.Z., Ramasamy, K.

Effects of commercial oligosaccharides on growth of selected beneficial and non-beneficial gut bacteria of broilers by Wong, L. L., Sieo, Chin Chin, Ramasamy, K., Ho, Yin Wan

Get full text

Organotin Dithiocarbamates: Single-Source Precursors for Tin Sulfide Thin Films by Aerosol-Assisted Chemical Vapor Deposition (AACVD) by Ramasamy, K, Kuznetsov, V, Gopal, K, Malik, M, Raftery, J, Edwards, P, O'Brien, P

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment by Olechnowicz, SWZ, Weivoda, MM, Lwin, ST, Leung, SK, Gooding, S, Nador, G, Javaid, MK, Ramasamy, K, Rao, SR, Edwards, JR, Edwards, CM

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity by Gooding, S, Bjorklund, C, Amatangelo, M, Ren, Y, Marella, M, Couto, S, Park, C, Lata, S, Nibhani, R, Towfic, F, Oppermann, U, Ramasamy, K, Pierceall, W, Vyas, P, Thakurta, A

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysi... by Lee, HC, Ramasamy, K, Macro, M, Davies, FE, Abonour, R, van Rhee, F, Hungria, VTM, Puig, N, Ren, K, Silar, J, Enwemadu, V, Cherepanov, D, Leleu, X

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs by Kolovos, S, Nador, G, Kishore, B, Streetly, M, Rabin, N, Chantry, A, Yong, K, Ashcroft, J, Bowcock, S, Drayson, M, Ramasamy, K, Prieto Alhambra, D, Cooper, C, Javaid, M, Pinedo Villanueva, R

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma by Gooding, S, Ansari-Pour, N, Towfic, F, Ortiz Estévez, M, Chamberlain, PP, Tsai, K-T, Flynt, E, Hirst, M, Rozelle, D, Dhiman, P, Neri, P, Ramasamy, K, Bahlis, N, Vyas, P, Thakurta, A

Elective vs non-elective hospital admissions by patients with multiple myeloma in England 2014 - 2018 by Ramasamy, K, Kolovos, S, Nador, G, Finley, R, Streetly, M, Kishore, B, Rabin, N, Chantry, A, Yong, K, Ashcroft, J, Bowcock, S, Drayson, M, Prieto Alhambra, D, Cooper, C, Javaid, M, Pinedo Villanueva, R

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response by Ramasamy, K, Sadler, R, Jeans, S, Weeden, P, Varghese, S, Turner, A, Larham, J, Gray, N, Carty, O, Barrett, J, Bowcock, S, Oppermann, U, Cook, G, Kyriakou, C, Drayson, M, Basu, S, Moore, S, McDonald, S, Gooding, S, Javaid, MK

Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers by Agarwal, G, Nador, G, Varghese, S, Getu, H, Palmer, C, Rodgers, C, Pereira, C, Sallemi, G, Partington, K, Patel, N, Soundarajan, R, Mills, R, Brouwer, R, Shah, A, Peppercorn, D, Edwards, C, Javaid, M, Gooding, S, Ramasamy, K

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease by Gooding, S, Olechnowicz, S, Morris, E, Armitage, A, Arezes, J, Frost, J, Repapi, E, Edwards, J, Ashley, N, Waugh, C, Gray, N, Martinez-Hackert, Lim, PJ, Pasricha, S-R, Knowles, H, Mead, A, Ramasamy, K, Drakesmith, A, Edwards, C

Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma by Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination by Twumasi, C, Moore, S, Sadler, R, Jeans, S, Varghese, S, Turner, A, Agarwal, G, Larham, J, Gray, N, Carty, O, Barrett, J, Bowcock, S, Oppermann, U, Gamble, V, Cook, G, Kyriakou, C, Drayson, M, Basu, S, McDonald, S, McKinley, S, Gooding, S, Javaid, MK, Ramasamy, K

Prospective assessment of tumour burden and bone disease in plasma cell dyscrasias using DW-MRI and exploratory bone biomarkers by Agarwal, G, Nador, G, Varghese, S, Getu, H, Palmer, C, Watson, E, Pereira, C, Sallemi, G, Partington, K, Patel, N, Soundarajan, R, Mills, R, Brouwer, R, Maritati, M, Shah, A, Peppercorn, D, Oppermann, U, Edwards, CM, Rodgers, CT, Javaid, MK, Gooding, S, Ramasamy, K

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma by Kurata, K, James-Bott, A, Tye, MA, Yamamoto, L, Samur, MK, Tai, Y-T, Dunford, J, Johansson, C, Senbabaoglu, F, Philpott, M, Palmer, C, Ramasamy, K, Gooding, S, Smilova, M, Gaeta, G, Guo, M, Christianson, JC, Payne, NC, Singh, K, Karagoz, K, Stokes, ME, Ortiz, M, Hagner, P, Thakurta, A, Cribbs, A, Mazitschek, R, Hideshima, T, Anderson, KC, Oppermann, U